Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UI05MSP015CT · 1 trial · 1 indication
Change of symptom score of functional dyspepsia was evaluated by symptom-specific questionnaire.
| Arm | Type | Description |
|---|---|---|
| UI05MSP015CT | EXPERIMENTAL | UI05MSP015CT and Placebo of Gasmotin |
| Gasmotin | ACTIVE_COMPARATOR | Placebo of UI05MSP015CT and Gasmotin |
| Name | Type | Description |
|---|---|---|
| UI05MSP015CT | DRUG | UI05MSP015CT and Placebo of Gasmotin |
| Gasmotin | DRUG | Placebo of UI05MSP015CT and Gasmotin |
Inclusion Criteria: 1. Age \>19 years 2. Diagnosis of functional dyspepsia meeting Rome III criteria 3. At least three moderate or severe symptoms included in the Symptom Score 4. No structural lesions of upper gastrointestinal tract Exclusion Criteria: 1. History of dyspepsia unrelated to functi...
UI05MSP015CT is an investigational small molecule being developed for the treatment of functional dyspepsia, a gastrointestinal condition. It is currently in Phase 3 clinical development. The drug has been studied in a completed Phase 3 trial that enrolled 143 participants.
UI05MSP015CT is being developed by United Therapeutics Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol UTHR. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with functional dyspepsia.
UI05MSP015CT is in Phase 3 clinical development for functional dyspepsia. A Phase 3 trial has been completed, with 143 participants enrolled. The drug is investigational and has not been approved by regulatory authorities.
UI05MSP015CT has been studied in one completed Phase 3 clinical trial, identified as NCT03225248. This randomized, double-blind, active-controlled study evaluated the efficacy and safety of UI05MSP015CT in 143 participants with functional dyspepsia.
UI05MSP015CT is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for functional dyspepsia. The completed Phase 3 trial, NCT03225248, has finished, but the drug has not received regulatory approval.